Table 1.
Demographic and Clinical Characteristic of Participants
| Variables | N (%) | No-Mild Fatigue |
Mod-Severe Fatigue |
P-value |
|---|---|---|---|---|
| Total | 1,103 | 487 (44.15) | 616 (55.85) | |
| Age, years | 0.021 | |||
| <55 | 212 (19.22) | 76 (35.85) | 136 (64.15) | |
| 55–65 | 515 (46.69) | 233 (45.24) | 282 (54.76) | |
| >65 | 376 (34.09) | 178 (47.34) | 198 (52.66) | |
| Race/Ethnicity | 0.033 | |||
| White | 912 (82.68) | 416 (45.61) | 496 (54.39) | |
| Non-white | 191 (17.32) | 71 (37.17) | 120 (62.83) | |
| Employment (n=1 missing data) | 0.120 | |||
| Full-time | 423 (38.38) | 189 (44.68) | 234 (55.32) | |
| Part-time | 151 (13.70) | 77 (50.99) | 74 (49.01) | |
| Not employed | 528 (47.91) | 220 (41.67) | 308 (58.33) | |
| Education (n=1 missing data) | 0.059 | |||
| High school or less | 225 (20.42) | 112 (49.78) | 113 (50.22) | |
| College or more | 877 (79.58) | 375 (42.76) | 502 (57.24) | |
| Body Mass Index (Kg/m2) | <0.001 | |||
| <25 | 426 (38.62) | 222 (52.11) | 204 (47.89) | |
| 25–30 | 325 (29.47) | 143 (44.00) | 182 (56.00) | |
| >30 | 352 (31.91) | 122 (34.66) | 230 (65.34) | |
| Cancer Stage (n=12 missing data) | 0.085 | |||
| 0 & I | 568 (52.06) | 260 (45.77) | 308 (54.23) | |
| II | 382 (35.01) | 170 (44.50) | 212 (55.50) | |
| III | 141 (12.92) | 50 (35.46) | 91 (64.54) | |
| Years since breast cancer diagnosis | 0.045 | |||
| >5 | 190 (17.23) | 91 (47.89) | 99 (52.11) | |
| 2–5 | 423 (38.35) | 200 (47.28) | 223 (52.72) | |
| <2 | 490 (44.42) | 196 (40.00) | 294 (60.00) | |
| Chemotherapy | 0.045 | |||
| None | 534 (48.41) | 250 (46.82) | 284 (53.18) | |
| Chemo without Taxane | 105 (9.52) | 52 (49.52) | 53 (50.48) | |
| Chemo with Taxane | 464 (42.07) | 185 (39.87) | 279 (60.13) | |
| Radiotherapy | 0.474 | |||
| None | 311 (28.20) | 132 (42.44) | 179 (57.56) | |
| Yes | 792 (71.80) | 355 (44.82) | 437 (55.18) | |
| Surgery (n=1 missing data) | 0.011 | |||
| Lumpectomy | 638 (57.89) | 302 (47.34) | 336 (52.66) | |
| Mastectomy | 464 (42.11) | 184 (39.66) | 280 (60.34) | |
| Aromatase Inhibitors, current (n=6 missing data) | 0.721 | |||
| Anastrozole (Arimidex) | 884 (80.58) | 384 (43.44) | 500 (56.56) | |
| Exemestane (Aromasin) | 61 (5.56) | 28 (45.90) | 33 (54.10) | |
| Letrozole (Femara) | 152 (13.86) | 71 (46.71) | 81 (53.29) | |
| Duration of AI use, years | 0.059 | |||
| >3 | 272 (24.66) | 136 (50.00) | 136 (50.00) | |
| 1–3 | 565 (51.22) | 244 (43.19) | 321 (56.81) | |
| <1 | 266 (24.12) | 107 (40.23) | 159 (59.77) |